Literature DB >> 21819236

Using genome-wide association studies to identify genes important in serious adverse drug reactions.

Ann K Daly1.   

Abstract

Genome-wide association (GWA) studies have detected novel associations for serious, idiosyncratic, adverse drug reactions including liver toxicity, hypersensitivity, skin rash, and myotoxicity. Human leukocyte antigen (HLA) genotype has been established as an important predictor of susceptibility to drug-induced liver injury, including injury with some drugs where immune-related toxicity was not suspected previously. Similarly, GWA studies have shown a key role for HLA genotype in susceptibility to carbamazepine-related skin rash and hypersensitivity. HLA genotype is not a risk factor for all forms of drug-induced liver injury or for myotoxicity or cardiotoxicity. For simvastatin-related myotoxicity, a strong association with SLCO1B1, which encodes the hepatic statin uptake transporter, has been detected. Genome-wide studies have not yet found clear associations for drug-induced cardiotoxicity, but for bisphosphonate-induced necrosis of the jaw, polymorphisms in the cytochrome P450 CYP2C8 may predict susceptibility. Larger GWA studies and whole-genome sequencing may provide additional insights into all these toxicities.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21819236     DOI: 10.1146/annurev-pharmtox-010611-134743

Source DB:  PubMed          Journal:  Annu Rev Pharmacol Toxicol        ISSN: 0362-1642            Impact factor:   13.820


  31 in total

Review 1.  Clinical association between pharmacogenomics and adverse drug reactions.

Authors:  Zhi-Wei Zhou; Xiao-Wu Chen; Kevin B Sneed; Yin-Xue Yang; Xueji Zhang; Zhi-Xu He; Kevin Chow; Tianxin Yang; Wei Duan; Shu-Feng Zhou
Journal:  Drugs       Date:  2015-04       Impact factor: 9.546

Review 2.  Genetics of congenital and drug-induced long QT syndromes: current evidence and future research perspectives.

Authors:  Saagar Mahida; Andrew J Hogarth; Campbell Cowan; Muzahir H Tayebjee; Lee N Graham; Christopher B Pepper
Journal:  J Interv Card Electrophysiol       Date:  2013-03-21       Impact factor: 1.900

Review 3.  Personalized medicine: Genetic risk prediction of drug response.

Authors:  Ge Zhang; Daniel W Nebert
Journal:  Pharmacol Ther       Date:  2017-02-14       Impact factor: 12.310

4.  Hepatic differentiation and maturation of human embryonic stem cells cultured in a perfused three-dimensional bioreactor.

Authors:  Louise Sivertsson; Jane Synnergren; Janne Jensen; Petter Björquist; Magnus Ingelman-Sundberg
Journal:  Stem Cells Dev       Date:  2012-11-02       Impact factor: 3.272

Review 5.  Progress towards the integration of pharmacogenomics in practice.

Authors:  Sean D Mooney
Journal:  Hum Genet       Date:  2014-09-11       Impact factor: 4.132

Review 6.  Comparative epidemiology of hospital-acquired adverse drug reactions in adults and children and their impact on cost and hospital stay--a systematic review.

Authors:  Lateef Mohiuddin Khan
Journal:  Eur J Clin Pharmacol       Date:  2013-08-17       Impact factor: 2.953

7.  Genome-Wide Association Studies for Idiosyncratic Drug-Induced Hepatotoxicity: Looking Back-Looking Forward to Next-Generation Innovation.

Authors:  Zelalem Petros; Eyasu Makonnen; Eleni Aklillu
Journal:  OMICS       Date:  2017-02-16

Review 8.  Regulation of drug-induced liver injury by signal transduction pathways: critical role of mitochondria.

Authors:  Derick Han; Lily Dara; Sanda Win; Tin Aung Than; Liyun Yuan; Sadeea Q Abbasi; Zhang-Xu Liu; Neil Kaplowitz
Journal:  Trends Pharmacol Sci       Date:  2013-02-28       Impact factor: 14.819

Review 9.  Safety of Nanoparticles in Medicine.

Authors:  Joy Wolfram; Motao Zhu; Yong Yang; Jianliang Shen; Emanuela Gentile; Donatella Paolino; Massimo Fresta; Guangjun Nie; Chunying Chen; Haifa Shen; Mauro Ferrari; Yuliang Zhao
Journal:  Curr Drug Targets       Date:  2015       Impact factor: 3.465

Review 10.  Pharmacogenomics in clinical practice and drug development.

Authors:  Andrew R Harper; Eric J Topol
Journal:  Nat Biotechnol       Date:  2012-11-08       Impact factor: 54.908

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.